Online Inquiry

Global Services. (Creative Biolabs Authorized)

Replication-Competent AAV (RCA) Contamination Auditing Service

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

The production of recombinant adeno-associated virus (AAV) vectors is often challenged by replication-competent AAV (RCA) contamination, which can compromise therapeutic safety and regulatory compliance. To address this critical issue, we offer specialized RCA Contamination Auditing Services designed for precise and reliable detection. Our service employs highly sensitive, validated assays to rigorously identify RCA contaminants across various AAV serotypes and production stages. With exceptional specificity, low detection limits, and full adherence to guidelines, our auditing empowers you to ensure vector purity, accelerate regulatory approval, and safeguard patient outcomes in gene therapy programs.

Introduction

Replication-competent AAV (rcAAV) refers to wild-type-like adeno-associated virus particles that arise during the production of recombinant AAV vectors, typically through homologous recombination between packaging plasmids and helper virus sequences. In CAR-T cell manufacturing, rcAAV contamination poses a critical safety risk, as it can lead to unintended transduction of producer cells, generate infectious viral particles, and potentially compromise the genomic integrity and clonal stability of the final therapeutic product. Consequently, the complete elimination of rcAAV from the rAAV production system is essential for ensuring the safety, regulatory compliance, and clinical reliability of CAR-T cell therapies.

Fig.1 Removing wild-type–like AAV particles that are capable of replication from a recombinant AAV production platform. (OA Literature) Fig.1 Eliminating AAV particles that mimic wild-type and possess replication capability from a rAAV production environment.¹

Our Service

Our Replication-Competent AAV (RCA) Contamination Auditing Services provide precise detection and quantification of RCA in gene therapy products. Leveraging validated assays and regulatory expertise, we ensure vector safety and process integrity. Our services help you mitigate risks, streamline regulatory approval, and maintain high-quality standards in AAV manufacturing.

What We Can Offer

To ensure the safety and regulatory compliance of AAV-based gene therapies, we offer a comprehensive suite of RCA detection and characterization services, ranging from gold-standard infectivity assays to high-resolution molecular and spatial analysis platforms.

Featured services of RCA contamination auditing services at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

We require the purified bulk drug substance at the end of production, or the final drug product formulation.

Key Steps:

Workflow of RCA contamination auditing services at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

RCA Titer Quantification.
Impurity Profiling: We provide a detailed classification of all impurities other than RCA present in the sample.

Key Advantages

Exceptional Detection Speed: Our service dramatically shortens the detection timeline from weeks to hours using advanced PCR-based technologies.
Superior Sensitivity: It achieves a significantly lower limit of detection compared to traditional methods, enabling early identification of trace-level contamination.
High-throughput and Objective Quantification: Automated digital PCR provides unbiased, highly reproducible, and scalable data analysis, eliminating the subjectivity and variability of manual microscopy.
Standardized Process for Diverse Vector Systems: It offers customized, sensitive protocols for AAV, adenovirus, and lentivirus/retrovirus systems, ensuring a broadly applicable safety auditing strategy.

FAQ

Q1: What is RCA, and why does it raise safety issues in AAV manufacturing?

A1: RCA refers to wild-type or replication-competent AAV variants that may emerge during vector production. Their presence can lead to unintended replication, immune responses, or off-target activity in patients, which is why regulatory bodies mandate RCA testing for product safety.

Q2: Which sample types are suitable for your RCA auditing service?

A2: We process bulk harvests, purified AAV drug substances, final product lots, and in-process materials such as cell lysates or supernatants. Detailed instructions for sample handling and shipping are provided once the service is confirmed.

Why Choose Us?

Choose us for unparalleled RCA detection expertise, validated sensitive assays, and strict regulatory alignment. We deliver rapid, reliable auditing to safeguard your AAV products. Our tailored solutions minimize false positives, accelerate timelines, and ensure patient safety, making us the trusted partner for gene therapy quality assurance and regulatory compliance.

Customer Reviews

"Before engaging the Replication-Competent AAV (RCA) Contamination Auditing Services, inconsistent RCA levels compromised the reproducibility of our preclinical data. This auditing service allowed us to accurately map contamination hotspots, notably identifying risks during upstream plasmid transfection. The detailed report guided us in adjusting our packaging plasmid design, ultimately reducing RCA to below detectable limits and eliminating guesswork in later process development." Dr. Emily Carter.

"As our lab transitioned from academic research to clinical applications, a major hurdle was our lack of systematic RCA screening experience. The RCA Contamination Auditing Services not only assessed contamination in our existing viral vector stocks but also delivered a standardized audit workflow and staff training. The auditing team helped us establish a simplified yet effective in-house RCA monitoring system, enabling us to ensure animal study data integrity despite limited resources." Prof. David Chen.

How to contact us?

Reach out today to safeguard your AAV pipeline with expert RCA auditing. Our team is ready to discuss your specific quality control needs, customize testing strategies, and provide rapid, reliable assessments. Contact us to request a quote or schedule a technical consultation—your path to regulatory confidence starts here.

Reference

Dong, Biao et al. "A concept of eliminating nonhomologous recombination for scalable and safe AAV vector generation for human gene therapy." Nucleic acids research vol. 41,13 (2013): 6609-17. Distributed under Open Access License CC BY 3.0, without modification. https://doi.org/10.1093/nar/gkt404.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.